|
Segment Information Segment Information (Details) (USD $) In Millions, unless otherwise specified
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
Dec. 31, 2013
|
Dec. 31, 2014
|
Sep. 30, 2014
|
Jun. 30, 2014
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
|
|
|
|
|
|
|
$ 1,379.0us-gaap_DepreciationDepletionAndAmortization |
$ 1,445.6us-gaap_DepreciationDepletionAndAmortization |
$ 1,462.2us-gaap_DepreciationDepletionAndAmortization |
| Revenue |
|
5,121.3us-gaap_Revenues |
4,875.6us-gaap_Revenues |
4,935.6us-gaap_Revenues |
4,683.1us-gaap_Revenues |
5,808.8us-gaap_Revenues |
5,772.6us-gaap_Revenues |
5,929.7us-gaap_Revenues |
5,602.0us-gaap_Revenues |
19,615.6us-gaap_Revenues |
23,113.1us-gaap_Revenues |
22,603.4us-gaap_Revenues |
| Long-Lived Assets |
8,741.3us-gaap_NoncurrentAssets |
8,547.2us-gaap_NoncurrentAssets |
|
|
|
8,741.3us-gaap_NoncurrentAssets |
|
|
|
8,547.2us-gaap_NoncurrentAssets |
8,741.3us-gaap_NoncurrentAssets |
8,990.5us-gaap_NoncurrentAssets |
| Asset impairment, restructuring, and other special charges |
|
(401.0)us-gaap_RestructuringSettlementAndImpairmentProvisions |
(36.3)us-gaap_RestructuringSettlementAndImpairmentProvisions |
0us-gaap_RestructuringSettlementAndImpairmentProvisions |
(31.4)us-gaap_RestructuringSettlementAndImpairmentProvisions |
(35.4)us-gaap_RestructuringSettlementAndImpairmentProvisions |
0us-gaap_RestructuringSettlementAndImpairmentProvisions |
(63.5)us-gaap_RestructuringSettlementAndImpairmentProvisions |
(21.7)us-gaap_RestructuringSettlementAndImpairmentProvisions |
(468.7)us-gaap_RestructuringSettlementAndImpairmentProvisions |
(120.6)us-gaap_RestructuringSettlementAndImpairmentProvisions |
(281.1)us-gaap_RestructuringSettlementAndImpairmentProvisions |
| Selling, General and Administrative Expense |
|
|
|
|
|
|
|
|
|
(6,620.8)us-gaap_SellingGeneralAndAdministrativeExpense |
(7,125.6)us-gaap_SellingGeneralAndAdministrativeExpense |
(7,513.5)us-gaap_SellingGeneralAndAdministrativeExpense |
| Income before income taxes |
|
513.6us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
655.5us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
940.4us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
890.8us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
909.9us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
1,513.4us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
1,514.9us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
1,951.1us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
3,000.3us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
5,889.3us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
5,408.2us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
| Acquired in-process research and development |
(57.1)lly_AcquiredInProcessResearchAndDevelopment |
(105.2)lly_AcquiredInProcessResearchAndDevelopment |
(95.0)lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
(57.1)lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
(200.2)lly_AcquiredInProcessResearchAndDevelopment |
(57.1)lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
| Gain (Loss) on Contract Termination |
|
|
|
|
|
|
|
|
|
0us-gaap_GainLossOnContractTermination |
495.4us-gaap_GainLossOnContractTermination |
787.8us-gaap_GainLossOnContractTermination |
| Other-net, (income) expense |
|
137.2us-gaap_NonoperatingIncomeExpense |
93.5us-gaap_NonoperatingIncomeExpense |
53.8us-gaap_NonoperatingIncomeExpense |
56.0us-gaap_NonoperatingIncomeExpense |
9.1us-gaap_NonoperatingIncomeExpense |
(31.3)us-gaap_NonoperatingIncomeExpense |
11.9us-gaap_NonoperatingIncomeExpense |
529.2us-gaap_NonoperatingIncomeExpense |
340.5us-gaap_NonoperatingIncomeExpense |
518.9us-gaap_NonoperatingIncomeExpense |
674.0us-gaap_NonoperatingIncomeExpense |
| United States [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
9,134.1us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_US |
12,889.7us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_US |
12,313.1us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_US |
| Long-Lived Assets |
4,649.6us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_US |
4,566.2us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_US |
|
|
|
4,649.6us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_US |
|
|
|
4,566.2us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_US |
4,649.6us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_US |
5,064.7us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_US |
| Europe [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
4,506.7us-gaap_Revenues / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
4,338.4us-gaap_Revenues / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
4,259.7us-gaap_Revenues / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
| Long-Lived Assets |
2,469.7us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
2,401.5us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
|
|
|
2,469.7us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
|
|
|
2,401.5us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
2,469.7us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
2,281.1us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = us-gaap_EuropeMember |
| JAPAN |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
2,027.1us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_JP |
2,063.8us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_JP |
2,246.2us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_JP |
| Long-Lived Assets |
81.1us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_JP |
80.4us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_JP |
|
|
|
81.1us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_JP |
|
|
|
80.4us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_JP |
81.1us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_JP |
101.5us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = country_JP |
| Other Foreign Countries [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
3,947.7us-gaap_Revenues / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
3,821.2us-gaap_Revenues / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
3,784.4us-gaap_Revenues / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
| Long-Lived Assets |
1,540.9us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
1,499.1us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
|
|
|
1,540.9us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
|
|
|
1,499.1us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
1,540.9us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
1,543.2us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = lly_OtherForeignCountriesMember |
| Total segment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Income before income taxes |
|
|
|
|
|
|
|
|
|
3,696.2us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_TotalSegmentMember |
5,571.6us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_TotalSegmentMember |
4,901.5us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_TotalSegmentMember |
| Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
6,939.0us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
7,304.4us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
6,810.9us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Neuroscience [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
3,596.5us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
7,216.2us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
7,575.1us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
| Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
3,393.0us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
3,268.5us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
3,281.6us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
| Cardiovascular [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
3,053.5us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
2,923.2us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
2,632.5us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
| Other Pharmaceuticals [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
287.0us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_OtherPharmaceuticalsMember |
249.3us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_OtherPharmaceuticalsMember |
266.8us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_OtherPharmaceuticalsMember |
| Human Pharmaceutical Products Total [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
|
|
|
|
|
|
|
1,270.0us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
1,350.0us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
1,370.0us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
| Revenue |
|
|
|
|
|
|
|
|
|
17,269.0us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
20,961.6us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
20,566.9us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
| Income before income taxes |
|
|
|
|
|
|
|
|
|
3,132.0us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
5,015.0us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
4,393.4us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_PharmaceuticalProductsTotalMember |
| Animal Health Products [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
|
|
|
|
|
|
|
111.5us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
99.4us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
91.1us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
| Revenue |
|
|
|
|
|
|
|
|
|
2,346.6us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
2,151.5us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
2,036.5us-gaap_Revenues / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
| Income before income taxes |
|
|
|
|
|
|
|
|
|
564.2us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
556.6us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
508.1us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments / us-gaap_StatementBusinessSegmentsAxis = lly_AnimalHealthProductsMember |
| Corporate, Non-Segment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Asset impairment, restructuring, and other special charges |
|
|
|
|
|
|
|
|
|
(468.7)us-gaap_RestructuringSettlementAndImpairmentProvisions / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
(120.6)us-gaap_RestructuringSettlementAndImpairmentProvisions / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
(281.1)us-gaap_RestructuringSettlementAndImpairmentProvisions / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
| Selling, General and Administrative Expense |
|
|
|
|
|
|
|
|
|
(119.0)us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
0us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
0us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
| Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
(200.2)lly_AcquiredInProcessResearchAndDevelopment / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
(57.1)lly_AcquiredInProcessResearchAndDevelopment / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
0lly_AcquiredInProcessResearchAndDevelopment / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
| Amylin [Member] | Corporate, Non-Segment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Gain (Loss) on Contract Termination |
|
|
|
|
|
|
|
|
|
0us-gaap_GainLossOnContractTermination / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
495.4us-gaap_GainLossOnContractTermination / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
787.8us-gaap_GainLossOnContractTermination / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
| Cymbalta [Member] | Neuroscience [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
1,614.7us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_CymbaltaMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
5,084.4us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_CymbaltaMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
4,994.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_CymbaltaMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
| Humalog [Member] | Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
2,785.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_HumalogMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
2,611.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_HumalogMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
2,395.5us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_HumalogMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Humulin [Member] | Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
1,400.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_HumulinMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
1,315.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_HumulinMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
1,239.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_HumulinMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Forteo [Member] | Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
1,322.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ForteoMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
1,244.9us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ForteoMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
1,151.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ForteoMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Evista [Member] | Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
419.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_EvistaMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
1,050.4us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_EvistaMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
1,010.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_EvistaMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Trajenta (BI) [Member] | Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
328.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_TrajentaBIMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
249.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_TrajentaBIMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
88.6us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_TrajentaBIMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Other Endocrinology [Member] | Endocrinology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
683.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherEndocrinologyMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
832.9us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherEndocrinologyMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
926.6us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherEndocrinologyMember / us-gaap_StatementBusinessSegmentsAxis = lly_EndocrinologyMember |
| Zyprexa [Member] | Neuroscience [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
1,037.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ZyprexaMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
1,194.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ZyprexaMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
1,701.4us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ZyprexaMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
| Strattera [Member] | Neuroscience [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
738.5us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_StratteraMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
709.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_StratteraMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
621.4us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_StratteraMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
| Other Neuroscience [Member] | Neuroscience [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
206.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherNeuroscienceMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
227.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherNeuroscienceMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
258.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherNeuroscienceMember / us-gaap_StatementBusinessSegmentsAxis = lly_NeuroscienceMember |
| Alimta [Member] | Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
2,792.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_AlimtaMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
2,703.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_AlimtaMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
2,594.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_AlimtaMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
| Erbitux [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
373.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
373.7us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
397.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
| Erbitux [Member] | Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
373.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
373.7us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
397.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
| Other Oncology [Member] | Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
227.7us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherOncologyMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
191.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherOncologyMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
290.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherOncologyMember / us-gaap_StatementBusinessSegmentsAxis = lly_OncologyMember |
| Cialis [Member] | Cardiovascular [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
2,291.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_CialisMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
2,159.4us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_CialisMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
1,926.8us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_CialisMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
| Effient [Member] | Cardiovascular [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
522.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_EffientMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
508.7us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_EffientMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
457.2us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_EffientMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
| Other Cardiovascular [Member] | Cardiovascular [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
240.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherCardiovascularMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
255.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherCardiovascularMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
248.5us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_OtherCardiovascularMember / us-gaap_StatementBusinessSegmentsAxis = lly_CardiovascularMember |
| BI compounds [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Other-net, (income) expense |
|
92.0us-gaap_NonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_BiCompoundsMember |
|
|
|
|
|
|
|
|
|
|
| BI compounds [Member] | Corporate, Non-Segment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Other-net, (income) expense |
|
|
|
|
|
|
|
|
|
$ 92.0us-gaap_NonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_BiCompoundsMember / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
$ 0us-gaap_NonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_BiCompoundsMember / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
$ 0us-gaap_NonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_BiCompoundsMember / us-gaap_StatementBusinessSegmentsAxis = us-gaap_CorporateNonSegmentMember |
| Minimum [Member] | Sales Revenue, Goods, Net [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration Risk, Percentage |
|
|
|
|
|
|
|
|
|
8.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_RangeAxis = us-gaap_MinimumMember |
10.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_RangeAxis = us-gaap_MinimumMember |
10.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_RangeAxis = us-gaap_MinimumMember |
| Minimum [Member] | Accounts Receivable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration Risk, Percentage |
|
|
|
|
|
|
|
|
|
9.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_RangeAxis = us-gaap_MinimumMember |
9.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_RangeAxis = us-gaap_MinimumMember |
9.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_RangeAxis = us-gaap_MinimumMember |
| Maximum [Member] | Sales Revenue, Goods, Net [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration Risk, Percentage |
|
|
|
|
|
|
|
|
|
19.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_RangeAxis = us-gaap_MaximumMember |
19.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_RangeAxis = us-gaap_MaximumMember |
19.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesRevenueGoodsNetMember / us-gaap_RangeAxis = us-gaap_MaximumMember |
| Maximum [Member] | Accounts Receivable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration Risk, Percentage |
|
|
|
|
|
|
|
|
|
18.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_RangeAxis = us-gaap_MaximumMember |
18.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_RangeAxis = us-gaap_MaximumMember |
18.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_RangeAxis = us-gaap_MaximumMember |